Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

NeuVasQ Biotechnologies

Request full access

Developing pharmaceuticals to restore blood-brain barrier function in acute neurological disorders such as stroke, epilepsy, and neurodegenerative diseases like Alzheimer’s

Charleroi, BelgiumFounded 2021Biotech & Life Sciences

About NeuVasQ Biotechnologies

NeuVasQ Biotechnologies is a biopharmaceutical company focused on developing treatments for neurological disorders by restoring the integrity of the blood-brain and blood-retina barriers. The company was founded in 2021 as a spin-off from the Université Libre de Bruxelles (ULB) and is headquartered in Gosselies, Belgium.

The company's scientific foundation is based on the research of its founder, Professor Benoît Vanhollebeke, Director of the Laboratory of Neurovascular Signaling at ULB. His work centers on the molecular mechanisms that form and maintain the blood-brain barrier (BBB), particularly the role of the Wnt signaling pathway. Instead of trying to bypass the BBB to deliver drugs, NeuVasQ's approach is to repair the barrier itself, which can become permeable due to age or injury, leading to various neurological conditions.

NeuVasQ is pioneering first-in-class antibodies that target Gpr124 and Reck, proteins that act as cofactors in Wnt signaling, to selectively restore neurovascular function. This technology has potential applications for a range of conditions, including acute neurological disorders like stroke and epilepsy, neurodegenerative diseases such as Alzheimer's and Parkinson's, and vascular retinopathies like diabetic macular edema.

The company's business model is centered on research and development, with the goal of licensing its proprietary technologies and drug candidates to larger pharmaceutical partners. In June 2021, NeuVasQ secured approximately $24 million (€20 million) in a Series A funding round. The round was led by Newton Biocapital and included participation from public and private investors such as SFPI-FPIM, SRIW Life Sciences, and Theodorus, the ULB spin-off investment fund. In September 2022, Emmanuel Lacroix, a former Vice President at UCB Ventures, was appointed as CEO to lead the company through its next stage of development.

Source: Dealroom company data

At a glance

Status
Operational
Employees
15
Open positions
None listed
Dealroom signal
71.8/100
Industry
Health
Sub-industry
Pharmaceutical
Sector
Biotechnology, Neurology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Jun 2021 $22M $88M SFPIM · Wallonie Entreprendre · Newton BioCapital · Sambrinvest ↗
SPINOUT✓Other financing Feb 2021 $0 — Université libre de Bruxelles —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

YearProfitMargin
2026 —
2025 —
2024 —
2023 —
2022 —
2021 —
Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

NeuVasQ Biotechnologies website traffic

Latest recorded traffic for NeuVasQ Biotechnologies is 850 monthly website visits, up 8400% over the last three months. NeuVasQ Biotechnologies's team grew 7.1% over the past year.

Latest monthly visits850 3-month web change+8400% 1-year team growth+7.1%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

NeuVasQ Biotechnologies in the Charleroi ecosystem

Live from Dealroom

The NeuVasQ Biotechnologies office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

7 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A5 investors entered at this stage

  • Newton BioCapital
  • SFPIM
  • Wallonie Entreprendre
  • Sambrinvest
  • WE Venture

Other known investors2 additional known investors

  • Université libre de Bruxelles
  • Seido Capital
Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
3 countries with
team presence
🇧🇪 Belgium83.3%
🇮🇹 Italy8.3%
🇨🇦 Canada8.3%
3 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about NeuVasQ Biotechnologies on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See NeuVasQ Biotechnologies’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.